Texas AG Sues Dallas Doctor Over Transgender Care for Minors
Medically reviewed by Drugs.com.
By Robin Foster HealthDay Reporter
FRIDAY, Oct. 18, 2024 -- A Dallas doctor has been sued by Texas Attorney General Ken Paxton for allegedly providing transgender care to nearly two dozen minors in violation of state law.
In the lawsuit filed Thursday, Paxton claimed that Dr. May Chi Lau, who specializes in adolescent medicine, provided hormone replacement therapy to 21 minors who were transitioning from October 2023 to August 2024. Last year, Texas enacted a law banning hormone replacement therapy and other forms of gender-affirming care for minors.
“Texas passed a law to protect children from these dangerous unscientific medical interventions that have irreversible and damaging effects,” Paxton said in a statement announcing the lawsuit. “Doctors who continue to provide these harmful ‘gender-transition’ drugs and treatments will be prosecuted to the full extent of the law.”
The statement also claimed that Lau used "false diagnoses and billing codes" to mask "unlawful prescriptions."
Paxton’s suit is the first filed in the country by an attorney general against an individual doctor alleging violation of a restriction on transition-related care for minors, NBC News reported.
Neither Lau nor her employer, the University of Texas Southwestern Medical Center, responded to a request for comment from NBC News.
If Lau is found guilty, she could lose her medical license and face a financial penalty of hundreds of thousands of dollars, NBC News reported.
Texas’ law includes a provision that allows doctors to continue to prescribe puberty blockers and hormone therapy to patients who began treatment before June 1, 2023, to safely wean them off the medications, according to Paxton’s suit.
Minors are also required to have attended at least 12 counseling or psychotherapy sessions for at least six months before they start treatment. It wasn't clear whether Lau’s patients could fall under that provision, NBC News said.
Twenty-six states ban at least some forms of gender-affirming care for minors, according to the Movement Advancement Project, an LGBTQ think tank.
The U.S. Supreme Court is expected to hear oral arguments and rule this session on whether to strike down a similar law in Tennessee, NBC News reported. How the court rules on the Tennessee law will affect similar restrictions in other states.
Major medical organizations, such as the American Medical Association and the American Academy of Pediatrics, state that transition-related care is an effective and medically necessary way to treat gender dysphoria, which is distress felt by people whose gender identities differ from their genders assigned at birth.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-19 00:00
Read more
- GLP-1 Meds May Lower Clot Risk in People With Diabetes
- RSNA: Genicular Artery Embolization Effective, Safe for Knee Osteoarthritis
- 13.9 Percent of Older Adults Meet Federal Physical Activity Guidelines
- New Youth Mental Health Program Shows Promise
- FDA Revokes Emergency Use Authorization (EUA) for Bebtelovimab for the Treatment of COVID-19
- As Daily Steps Rise, Depression Levels Fall
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions